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Flucloxacillin is often used for the treatment of serious infections due to sensitive staphylococci. The
pharmacokinetic (PK)-pharmacodynamic (PD) breakpoint of flucloxacillin has not been determined by the use
of population PK. Targets based on the duration of non-protein-bound concentrations above the MIC (fT>MIC)
best correlate with clinical cure rates for beta-lactams. We compared the breakpoints for flucloxacillin between
several dosage regimens. In a randomized, two-way crossover study, 10 healthy volunteers received 500 mg and
1,000 mg flucloxacillin as 5-min intravenous infusions. Drug concentrations were determined by high-pressure
liquid chromatography. We used the programs WinNonlin for noncompartmental analysis and statistics and
NONMEM for population PK and Monte Carlo simulation. We compared the probability of target attainment
(PTA) for intermittent- and continuous-dosage regimens based on the targets of fT>MICs of >50% and >30% of
the dosing interval. The clearance and the volume of distribution were very similar after the administration
of 500 mg and 1,000 mg flucloxacillin. We estimated renal and nonrenal clearances of 5.37 liters/h (coefficient
of variation, 19%) and 2.73 liters/h (33%). For near maximal killing (target, fT>MIC of >50%) flucloxacillin
showed a robust (>90%) PTA up to MICs of 0.75 to 1 mg/liter (PTA of 86% at 1 mg/liter) for a continuous or
a prolonged infusion of 6 g/day. Short-term infusions of 6 g/day had a lower breakpoint of 0.25 to 0.375 mg/liter.
The flucloxacillin PK was linear for doses of 500 mg and 1,000 mg. Prolonged and continuous infusion at a 66%
lower daily dose achieved the same PK-PD breakpoints as short-term infusions. Prolonged infusion and
continuous infusion are appealing options for the treatment of serious infections caused by sensitive
staphylococci.
Flucloxacillin is an isoxazolyl penicillin and is active against
many gram-positive bacteria, including penicillinase-producing
staphylococci and streptococci, but not against methicillin-re-
sistant Staphylococcus aureus (20). In the United Kingdom
flucloxacillin remains the predominantly prescribed anti-
staphylococcal oral antibiotic (32). It is typically used for the
treatment of skin and soft tissue infections and respiratory
tract infections. For serious infections like endocarditis or
osteomyelitis caused by methicillin-susceptible S. aureus
(MSSA) it is administered intravenously as a slow injection, a
short-term infusion, or a continuous infusion. It has been re-
ported that limiting the use of glycopeptides could help to
control the emergence of resistance to vancomycin (10, 21).
Therefore, it might be preferable to use alternatives like flu-
cloxacillin instead of glycopeptides against MSSA, if the use of
the alternative grants a sufficient probability for a successful
clinical outcome. In addition, flucloxacillin has been suggested
to show more rapid killing of MSSA than vancomycin, and
flucloxacillin levels usually do not need to be monitored (23).
The clinical outcome for treatment with beta-lactams is re-
lated to the proportion of the dosing interval for which non-
protein-bound plasma concentrations exceed the MIC
(fTMIC) (12, 17). Attainment of the pharmacokinetic (PK)-
pharmacodynamic (PD) target of an fTMIC of 50% corre-
lates best with the near maximal bactericidal activity of peni-
cillins and is often used as a surrogate marker for successful
clinical outcome (2, 11–13, 17). For drugs with short half-lives,
like beta-lactams, prolonged and continuous infusions have
been shown to achieve a longer fTMIC than short-term infu-
sions at the same daily dose (15, 18). Therefore, prolonged or
continuous infusions may require lower daily doses compared
to those required for intermittent treatment while achieving
the same probability of target attainment (PTA) achieved with
high-dose intermittent treatment.
Conditions like endocarditis and osteomyelitis usually re-
quire prolonged high-dose treatment. Continuous-infusion
treatment can be managed at patients’ homes better than fre-
quent intermittent infusions (every 6 h [q6h] or q4h) and has
been reported to be efficacious for use for the completion of
treatment for serious staphylococcal infections at patients’
homes (22, 23). Flucloxacillin solutions have been reported to
be stable in water for injection for 7 days at 20 to 25°C (26).
However, the optimal doses for continuous and prolonged
infusion of flucloxacillin have not yet been determined by pop-
ulation PK and Monte Carlo simulation (MCS). In the absence
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of these data, some authors have reported that they adminis-
tered by continuous infusion the same daily doses that they
used for intermittent treatment (22, 23).
We used population PK and MCS to investigate the differ-
ences in the PK-PD target attainment between intermittent
and continuous infusions. To study dosage regimens by MCS
with various doses or other modes of administration, or both,
it is important to know whether the clearance changes with the
concentration in plasma at therapeutic concentrations. There-
fore, our second objective was to compare the PK of fluclox-
acillin at two different dose levels.
MATERIALS AND METHODS
Study participants. Ten healthy Caucasian subjects (five males and five fe-
males) participated in the study. Prior to entry into the study, all subjects were
given a physical examination, electrocardiography, and laboratory tests, includ-
ing urinalysis and screening for drugs of abuse. During the drug administration
periods, the volunteers were encouraged to report any discomfort or adverse
reactions and were closely observed by physicians. On each day of the study the
subjects were asked to complete a questionnaire on their health status. The study
was approved by the local ethics committee, and all subjects gave their written
informed consent prior to starting the study.
Study design and drug administration. The study was of a randomized, con-
trolled, two-way crossover design. In each of the two study periods, each subject
received a single dose of 500 mg or 1,000 mg flucloxacillin as a 5-min intravenous
infusion. Food and fluid intakes were strictly standardized on each study day. The
treatment periods were separated by a washout period of at least 4 days. The
subjects were requested to abstain from consuming alcohol and caffeine-con-
taining foods and beverages during the study periods.
Sampling schedule. All blood samples were drawn from a forearm vein via an
intravenous catheter placed on the forearm contralateral to the one used for
drug administration. Blood samples were drawn immediately before the start of
infusion; at the end of infusion; as well as at 5, 10, 15, 20, 25, 45, 60, 75, and 90
min and 2, 2.5, 3, 3.5, 4, 5, 6, 8, and 24 h after the end of the infusion. The samples
were cooled in an ice-water bath before centrifugation. After centrifugation the
plasma samples were immediately frozen and stored at 80°C until analysis.
Urine samples were collected immediately before the start of the infusion, from
the start of the infusion until 1 h after the end of the infusion, and at the
following time intervals: 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 8, 8 to 12, and
12 to 24 h after the end of the infusion. The urine samples were stored at 4°C
during the collection period. The amount and pH of the urine were measured.
Urine samples were immediately frozen and were stored at 80°C before anal-
ysis.
Determination of plasma and urine concentrations. For determination of the
flucloxacillin concentration in plasma, 100 l of the sample was deproteinized
with 200 l acetonitrile containing the internal standard. After mixing of the
solution and centrifugation at 15,000 rpm, 40 l was injected onto a high-
pressure liquid chromatography system. For determination of the flucloxacillin
concentration in urine, 20 l of the sample was diluted with 180 l water. After
the sample and water were mixed, 40 l was injected onto the high-pressure
liquid chromatography system. The flucloxacillin concentration was determined
by using a reversed-phase column and a potassium dihydrogen phosphate (pH
6.2)-acetonitrile mobile phase at a flow of 2 ml/min. Flucloxacillin and the
internal standard were detected at 220 nm.
The concentrations in the plasma and urine samples were measured against a
plasma or urine calibration curve. The calibration row in plasma was prepared
with a 10:1 dilution of tested drug-free plasma with a stock solution of fluclox-
acillin to obtain the highest calibration level. The other calibration levels were
obtained by 1:1 dilution of the highest calibration level or a level of higher
concentration with drug-free plasma. The calibration curve for urine was pre-
pared with a 10:1 dilution of tested drug-free urine with a stock solution to obtain
the highest calibration level. The other calibration levels were obtained by 1:1
dilution of the highest calibration level or a higher concentration with drug-free
urine. For the control of inter- and intra-assay variations, spiked quality controls
in plasma and urine were prepared by adding defined volumes of the stock
solution of flucloxacillin or the spiked control of a higher concentration to
defined volumes of tested drug-free plasma or urine.
No interferences were observed in plasma and urine for flucloxacillin or the
internal standard. Calibration was performed by linear regression. The linearity
of the flucloxacillin calibration curves in plasma and urine was demonstrated
from 0.500 to 250 mg/liter and 5.00 to 400 mg/liter, respectively. The quantifi-
cation limits were identical to the lowest calibration levels. The interday preci-
sion and the analytical recovery of the spiked quality control standards of flu-
cloxacillin in human plasma ranged from 4.1 to 7.7% and from 84.9 to 106.0%,
respectively. The interday precision and the analytical recovery of the spiked
quality control standards of flucloxacillin in human urine ranged from 3.3 to
5.1% and from 100.0 to 103.0%, respectively. The intraday precision and the
analytical recovery of the spiked quality control standards of flucloxacillin in
human plasma ranged from 3.9 to 7.0% and from 85.1 to 107.0%, respectively.
The intraday precision and the analytical recovery of the spiked quality control
standards of flucloxacillin in human urine ranged from 2.9 to 5.0% and from 99.0
to 103.2%, respectively.
Pharmacokinetics. (i) Noncompartmental analysis. The maximum concentra-
tion in plasma for each subject was read directly from the plasma concentration-
time curves. The area under the plasma concentration-time curve for each
subject was calculated by using the linear up/log down method, as implemented
in WinNonlin Professional (version 4.0.1) (30). This algorithm uses the linear
trapezoidal rule when concentrations are increasing or constant and the log-
trapezoidal rule when concentrations are decreasing.
(ii) Population PK analysis. We considered models with one, two, or three
disposition compartments and (i) first-order elimination, (ii) mixed-order
(Michaelis-Menten) elimination, or (iii) parallel first-order and mixed-order
elimination. The differential equations of our final model are as follows:
dX(1)
dt
 k01
(CLR  CLNR  CLicshallow  CLicdeep)
V1  X1

CLicshallow
V2  X2 
CLicdeep
V3  X3
dX2
dt

CLicshallow
V1  X1 
CLicshallow
V2  X2
dX3
dt

CLicdeep
V1  X1 
CLicdeep
V3  X3
dX4
dt

CLR
V1  X1
where X(1), X(2), and X(3) are the amounts of flucloxacillin in the central,
shallow peripheral, and deep peripheral compartments, respectively; X(4) is the
cumulative amount excreted unchanged in urine; CLR is renal clearance; CLNR
is nonrenal clearance; CLicshallow is the intercompartmental clearance between
the central and the shallow peripheral compartment; and CLicdeep is the inter-
compartmental clearance between the central and the deep peripheral compart-
ment. Drug input was described by a time-delimited zero-order input process
with rate k01. The analytical solution to these linear differential equations, as
implemented in NONMEM (ADVAN 11 and TRANS 4), was used for estima-
tion.
Competing models were discriminated by their predictive performance, as
assessed by visual predictive checks and the use of the NONMEM objective
function and residual plots.
For the visual predictive check, we simulated the plasma and urine profiles for
10,000 subjects by using the competing models. From these data we calculated
the median, the nonparametric 80% prediction interval (10th to 90th percen-
tiles), and the nonparametric 50% prediction interval (25th to 75th percentiles)
for the predicted concentrations in plasma and the amounts in urine. These
prediction interval lines were then overlaid on the original raw data. If the model
described the data correctly, then 20% of the observed data should fall outside
the 80% prediction interval at each time point and 50% of the data should fall
outside the interquartile range. We compared the median predicted concentra-
tions and the prediction intervals with the raw data and tested whether the
median and the prediction intervals mirrored the central tendency and the
variability of the raw data for the respective model.
(iii) Individual PK model. We estimated the between-subject variability (BSV)
for all parameters except the duration of the zero-order input and intercompart-
mental clearances. We assumed a log-normal distribution for the PK parameters
and used a full variance-covariance matrix to describe the variability of the PK
parameters as well as their pairwise correlations. The NONMEM program es-
timates BSV as variance. For more convenient interpretation, we report the
square root of the variance for BSV, as the square root of the variance is an
approximation of the apparent coefficient of variation of a normal distribution on
a log scale.
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(iv) Observation model. We described the residual unidentified variability by
using a combined additive and proportional error model for the concentrations
in plasma and the amounts excreted in urine.
(v) Computation. We used the first-order conditional estimation method with
the interaction estimation option in NONMEM (version V, release 1.1; NON-
MEM Project Group, University of California, San Francisco) (6) for all popu-
lation PK modeling and WinNonlin Professional (version 4.0.1; Pharsight Corp.,
Mountain View, CA) (30) for noncompartmental analysis and equivalence sta-
tistics.
(vi) MCS. We used fTMIC for at least 30% or 50% of the dosing interval as
PK-PD targets for flucloxacillin. An fTMIC of 50% is the target for the near
maximal bactericidal activity of penicillins, and an fTMIC of 30% is the target
for bacteriostasis (2, 11, 12, 14, 17). We calculated the PTA within the MIC range
from 0.0625 to 16 mg/liter, and as protein binding was not measured in the
current study, we used the protein binding of 96% for flucloxacillin that has been
reported in the literature (7, 8).
We compared three dosage regimens at a daily dose of 6 g: (i) continuous
infusion, (ii) prolonged (4 h) infusion of 2 g q8h, and (iii) a short-term (0.5 h)
infusion of 1.5 g q6h. In addition, we simulated 12 g flucloxacillin daily as 0.5-
h infusions of 2 g q4h. We simulated the plasma concentration time profiles of
10,000 virtual subjects for each dosage regimen at steady-state in absence of
residual error with NONMEM. The fTMIC values and the PTA were calculated
by linear interpolation between simulated concentrations (frequent sampling)
with Perl scripts, written by J. Bulitta. These Perl scripts were validated for all
dosage regimens studied for this and several other studies.
We used the population mean PK parameter estimates and the variance-
covariance matrix representing the BSV estimated by NONMEM for MCS and
assumed that the dose, duration of infusion, and timing of infusion had no
variability. We used the clearance and volume notation of our population PK
model during both estimation and MCS and assumed a normal distribution of
the PK parameters on a log scale, as described above.
We derived the PTA for each of the two targets by calculating the fraction of
subjects who attained the target at each MIC. The PK-PD breakpoint was
defined as the highest MIC for which the PTA was at least 90%. To put these
values into clinical perspective, the expectation value for the population PTA,
i.e., the expected population PTA for a specific dosage regimen and a specific
population of microorganisms, was calculated.
Statistical analysis. We tested the noncompartmental parameter estimates for
differences between treatments (500 mg and 1,000 mg flucloxacillin). We used
analysis of variance statistics on a log scale and an  level of significance of 0.05.
RESULTS
Demographics. All 10 subjects completed the study. The
median weight was 71 kg (range, 52 to 83 kg), the median
height was 178 cm (range, 165 to 190 cm), and the median age
was 25 years (range, 23 to 34 years). The subjects had normal
renal and hepatic functions.
Noncompartmental analysis. The flucloxacillin concentra-
tions in plasma and the amounts in urine after infusion of 500
mg and 1,000 mg are shown in Fig. 1. Table 1 shows the results
of the noncompartmental analysis. The peak concentrations
and the areas under the curve were dose linear. All other PK
parameters were very similar at both dose levels.
Population PK. The three-compartment model had a 200-
point better objective function and a better predictive perfor-
mance than the two-compartment model. A one-compartment
model was inappropriate for our data set. The parameter es-
timates for the three-compartment model are shown in Table
2, and the variance-covariance matrix is shown in Table 3.
Figure 2 shows the visual predictive checks for this model.
There was no indication that clearance decreased for the in-
crease in dose from 500 mg to 1,000 mg. The distributions of
subjects with lower and higher individual estimates for the
500-mg dose than for the 1,000-mg dose were five and five for
total clearance; five and five for renal clearance; and five and
five for nonrenal clearance. Thus, there was no trend of any
saturation of clearance at these dose levels. Three-compart-
ment models with mixed-order or parallel first-order and
mixed-order elimination yielded no significant improvement in
the objective function compared to that achieved with the
model with first-order elimination, and the parameter esti-
FIG. 1. Average  standard deviation profiles of flucloxacillin in
healthy volunteers after 5-min infusions of 500 mg and 1,000 mg
flucloxacillin.
TABLE 1. Pharmacokinetic parameters for 500 mg and 1,000 mg flucloxacillin from noncompartmental analysis
Parameter
Geometric mean (% CV) Point estimate (90% confidence interval)
for 1,000 mg/500 mg P value500 mg 1,000 mg
Total body clearance (liters/h) 8.16 (21) 8.18 (20) 100 (94–107) 0.94
Renal clearance (liters/h) 5.37 (22) 5.29 (22) 99 (90–108) 0.774
Nonrenal clearance (liters/h) 2.72 (30) 2.79 (33) 103 (88–119) 0.766
Fraction excreted unchanged in urine 0.66 (10) 0.65 (12) 98 (93–104) 0.62
Volume of distribution at steady state (liters) 9.63 (15) 9.97 (17) 104 (96–112) 0.44
Peak plasma concentration (mg/liter) 86.8 (13) 167 (16) 192 (175–211) 	0.01
Terminal half-life (h) 1.40 (26) 1.62 (25) 116 (87–153) 0.363
Mean residence time (h) 1.18 (19) 1.22 (14) 103 (97–110) 0.364
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mates of models with saturable elimination indicated no or
negligible saturation at the dose levels studied. We selected the
three-compartment model with first-order elimination as our
final model, as it had excellent predictive performance and as
the models with saturable elimination neither improved the
objective function significantly nor improved the predictive
performance.
MCSs. We compared the PTA versus MIC profiles for three
dosage regimens with a daily dose of 6 g and for one dosage
regimen at a daily dose of 12 g at two PK-PD targets (Fig. 3).
The PK-PD breakpoints for the targets of fTMIC of 50%
(near maximal bactericidal activity of penicillins) and fTMIC
of 30% (bacteriostasis) are shown in Table 4.
DISCUSSION
Flucloxacillin is indicated for the treatment of infections due
to susceptible gram-positive organisms, including beta-lacta-
mase-producing staphylococci and streptococci. It is used in-
travenously for the treatment of serious infections caused by
MSSA. In a randomized comparison trial with flucloxacillin (1
g q6h) and teicoplanin (6 mg/kg q12h for three doses and then
the same dose given once daily) for the treatment of burn
wound infections due to gram-positive pathogens, no signifi-
cant differences in the clinical and the microbiological success
rates between flucloxacillin and teicoplanin were found (33).
However, the rate of the emergence of resistance to glycopep-
tides is increasing, and restriction of their use has been re-
ported to be helpful in controlling vancomycin-resistant en-
terococci (10, 21). Therefore, it may be preferable to use
alternatives like flucloxacillin against MSSA whenever possible
in order to postpone and limit the use of glycopeptides.
The PK of flucloxacillin was studied by Nauta and Mattie
(29) during a 3-h infusion of 1.2 g/h (loading dose, 1 g) in
healthy volunteers. They reported average total, renal, and
nonrenal clearances of 7.4, 5.3, and 2.1 liters/h, respectively.
Adam et al. (1) found an average total clearance of 7.1 liters/h
in healthy volunteers after 1 g flucloxacillin was given as a
5-min intravenous infusion. Our results are in good agreement
with those clearances.
For beta-lactams like flucloxacillin, the clinical and microbi-
ological outcomes best correlate with fTMIC (12, 17). At the
same daily dose, prolonged or continuous infusions achieve a
longer fTMIC than intermittent short-term infusions. This is
especially evident for drugs with short half-lives, like beta-
lactams. Consequently, Drusano (18) proposed the use of pro-
longed infusions to optimize the PTAs of carbapenems.
We used population PK analysis and MCS to compare the
PTAs of short-term, prolonged, and continuous infusions for
flucloxacillin. MCS was shown to be a very useful tool for
rational dose selection for phase II/III clinical trials (19). Com-
pared to healthy volunteers, patients often have lower clear-
ances and larger volumes of distribution, which result in higher
average plasma concentrations and longer elimination half-
lives. Both these alterations of the PK in patients increase the
PTA. Thus, our estimates for the PTA in healthy volunteers
are conservative estimates for the PTA in patients. A higher
PTA for hospitalized patients compared to that for healthy
volunteers has also been shown by Lodise et al. (24) for pip-
eracillin given in combination with tazobactam.
To determine the PTA at various dose levels and for differ-
ent modes of administration, it is important to know whether
the clearance changes with the plasma concentration at ther-
apeutic concentrations. Therefore, we compared the PK
of flucloxacillin at two dose levels in a crossover study with
healthy volunteers.
Our noncompartmental analysis showed no differences in
the clearance or the volume of distribution between the low
and the high dose (Table 1). A three-compartment population
PK model with linear renal and nonrenal elimination showed
excellent predictive performance, and there was no indication
for a decrease in the total, renal, or nonrenal clearance with an
increase in the dose from 500 mg to 1,000 mg. Therefore, we
used this model, estimated from plasma and urine data at both
TABLE 2. Population parameter estimates
Parametera Unit Estimated valueb
CLT
c liters h1 8.10
CLR liters h
1 5.37 (19)
CLNR liters h
1 2.73 (33)
Vss
c liters 9.57
V1 liters 4.79 (17)
V2 liters 2.61 (37)
V3 liters 2.17 (15)
CLicshallow
d liters h1 15.3
CLicdeep
d liters h1 1.23
Tk0 (fixed) min 5
CVC % 9.4
SDC mg liter
1 0.155
CVAU % 20.9
SDAU mg 1.04
a CLT, total clearance; CLR, renal clearance; CLNR, nonrenal clearance; Vss,
volume of distribution at steady-state; V1, volume of distribution for the central
compartment; V2, volume of distribution for the shallow peripheral compart-
ment; V3, volume of distribution for the deep peripheral compartment;
CLicshallow, intercompartmental clearance between the central and the shallow
peripheral compartment; CLicdeep, intercompartmental clearance between the
central and the deep peripheral compartment; Tk0, duration of zero-order input
(not estimated); CVC, proportional residual error component for the plasma
concentrations; SDC, additive residual error component for the plasma concen-
trations; CVAU, proportional residual error component for the amounts excreted
in urine; SDAU, additive residual error component for the amounts excreted in
urine.
b The values for the structural PK parameters are geometric means (between-
subject coefficients of variation).
c Derived from parameter estimates (not estimated).
d No between subject variability included for distributional clearance.
TABLE 3. Variance-covariance matrix (on natural log scale)
for flucloxacillina
Parameter
Variance-covariance
CLR CLNR V1 V2 V3
CLR 0.0343
CLNR 0.0124 0.112
V1 0.00488 0.00551 0.0282
V2 0.0415 0.0641 0.00168 0.138
V3 0.0172 0.00804 0.0175 0.0351 0.023
a Log-normal distributions of the PK parameters were assumed. We did not
include the variability of the intercompartmental clearances in our parameter
variability model, as estimation of these variance and covariance terms did not
significantly improve the objective function and did not improve the predictive
performance shown in Fig. 2. See footnote a of Table 2 for the definitions of the
parameters.
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dose levels for MCS, to compare the PTA profiles with the
MIC profiles for four dosage regimens (Fig. 3). The target in
our MCS was based on the non-protein-bound plasma concen-
trations. A range of 94.6 to 96.2% for the plasma protein
binding of flucloxacillin has been reported (7, 9, 31). These
values correspond to a rather wide range for the non-protein-
bound fraction of 3.8 to 5.4%. This is a difference of 42% (5.4
versus 3.8%) for the non-protein-bound concentrations. To
account for this situation, we chose a relatively high protein
binding of 96%, which has also been reported by Bergan (7), as
this choice results in conservative (low) non-protein-bound
plasma concentrations.
For serious infections, doses of up to 8 g flucloxacillin per
day (2 g given three to four times daily) are recommended both
in the United Kingdom (4) and in Germany (5). As intrave-
nous flucloxacillin is more likely to be given for serious infec-
tions than for uncomplicated infections, we chose for our sim-
ulations a daily dose of 6 g, which is within the dose range
FIG. 2. Visual predictive check for concentrations in plasma and amounts excreted unchanged in urine: The plots show the raw data, the 80%
prediction interval (10th to 90th percentile), and the interquartile range (25th to 75th percentile). Ideally, 50% of the raw data should fall inside
the interquartile range at each time point and 80% of the raw data should fall inside the 80% prediction interval. The coefficient of correlation
for the observed versus the individual predicted concentrations was 0.987.
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recommended for the treatment of serious infections. Our
MCS with the bacteriostasis target (fTMIC  30%) showed
that prolonged infusion had a higher PTA than continuous
infusion and short-term infusion at the same daily dose (Table
4). For the target near maximal killing (fTMIC  50%), pro-
longed infusion and continuous infusion both had a three times
higher PK-PD breakpoint than short-term infusion at the same
daily dose of 6 g. Thus, prolonged infusion achieved a PTA
that was higher than or similar to the PTAs of the other two
regimens for both targets.
The different ranking of the three dosage regimens at the
same daily dose of 6 g for the two targets can be explained as
follows: the breakpoint for continuous infusion at steady state
is independent of the chosen target, as for any one patient
fTMIC can be only 0% or 100%. The profile for short-term
infusion shows a rather pronounced peak without a plateau,
and the profile for prolonged infusion shows a flat peak with a
rather broad plateau. Subsequently, short-term infusions reach
very high concentrations for a short period of time, and pro-
longed infusions reach moderately high concentrations, but for
a longer period of time. We determined for flucloxacillin that
short-term (0.5 h) infusions had the highest PTA for targets up
to fTMIC of 20%, prolonged (4-h) infusions performed best
for targets between 20% and 50%, and continuous infusion
had the highest PTA for longer targets (55% and above).
Continuous infusion was superior to short-term infusions for
targets of 30% and above (Fig. 4).
The PK-PD breakpoints need to be compared to the MICs
encountered in clinical practice to put these results into clinical
perspective. The MIC90s of flucloxacillin for MSSA are usually
reported to be0.5 mg/liter (22, 27, 28, 33). For an MIC of 0.5
mg/liter, continuous infusion and prolonged infusion of 6 g/day
had PTAs of more than 99%, whereas short-term infusion of 6
g/day reached a PTA of only 46%, based on the target for near
maximal killing. At an MIC of 1.0 mg/liter, a short-term infu-
sion of 2 g every 4 h had a PTA of more than 90% for the target
fTMIC of 50% (Table 4; Fig. 3).
The most relevant target depends on the clinical situation of
the patient. For patients with uncomplicated infections and an
intact immune system, it might be sufficient to achieve bacte-
riostasis. However, for serious infections the near maximal
bactericidal activity of the antibiotic might be required (17). As
flucloxacillin is also available for oral treatment, intravenous
dosing is more relevant for patients with serious infections.
As flucloxacillin showed no saturation in clearance, doubling
of the dose will yield concentrations twice as high and, there-
fore, PK-PD breakpoints twice as high. The PK-PD break-
points for an MCS with a daily dose of 12 g will be twice as high
as the PK-PD breakpoints for 6 g/day shown in Table 4, as
flucloxacillin exhibited linear pharmacokinetics. As the PK-PD
breakpoint of the short-term infusion q6h of 6 g/day was 0.25
mg/liter, a daily dose of about 12 g would be required to reach
a breakpoint of 0.5 mg/liter for near maximal killing. However,
4 g/day as a continuous or a prolonged infusion would be
sufficient to reach a breakpoint of 0.5 mg/liter.
The MIC90 of flucloxacillin is typically 0.5 mg/liter for
MSSA. Even without data on the distribution of the fluclox-
acillin MIC for MSSA, it is still possible to calculate the ex-
pectation value for the population PTA and an MIC90 of 0.5
mg/liter. The PTA-versus-MIC profile (Fig. 3) for continuous
or prolonged infusion of 4 g/day with a PK-PD breakpoint of
0.5 mg/liter can be roughly simplified to assuming a PTA of
100% for all MICs  0.5 mg/liter and a PTA of 0% for all
MICs above 0.5 mg/liter. For an MIC90 of 0.5 mg/liter, 90% of
the patients (PTA 
 100% for MICs  0.5 mg/liter) will
achieve the target (corresponding to the 90th percentile of the
MIC distribution) and 10% of the patients (PTA 
 0% for
MICs 0.5 mg/liter) will not achieve the target. Therefore, the
expectation value for the population PTA will be at least 90%
for prolonged or continuous infusion of 4 g/day and an MIC90
of 0.5 mg/liter. As described above, a dose of 12 g/day given as
short-term infusions q6h would be required to reach a PK-PD
breakpoint of 0.5 mg/liter and an expectation value of about
90% for an MIC90 of 0.5 mg/liter. This means that a 66% lower
FIG. 3. Probabilities of target attainment for different dosage regimens and PK-PD targets of flucloxacillin. Symbols: Œ, daily dose of 6 g
flucloxacillin, continuous infusion; , daily dose of 6 g flucloxacillin, 2 g q8h as a 4-h infusion; , daily dose of 6 g flucloxacillin, 1.5 g q6h as a
0.5-h infusion; F, daily dose of 12 g flucloxacillin, 2 g q4h as a 0.5-h infusion.
TABLE 4. Breakpoints of various dosage regimens for flucloxacillin
Dosage regimen Dailydose (g)
Breakpoint (mg/liter) for
fTMIC of:
50% 30%
2 g q8h as 4-h infusions 6 0.75 (86a) 1.5
6 g as continuous infusion 6 0.75 (86a) 0.75 (86a)
1.5 g q6h as 0.5-h infusions 6 0.25 (79b) 0.75 (83a)
2 g q4h as 0.5-h infusions 12 1 2
a Values in parentheses are the PTA (in percent) at 1 mg/liter.
b Value in parentheses is the PTA (in percent) at 0.375 mg/liter.
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daily dose is sufficient for continuous or prolonged infusion
compared to the dose required for short-term infusion q6h in
order to reach the same expectation value for a successful
clinical outcome.
Besides a cost reduction for drug acquisition secondary to
the dose reduction for prolonged or continuous infusion, a
lower risk of adverse events from flucloxacillin treatment is
probably a major advantage of prolonged and continuous in-
fusion. Cholestatic jaundice and hepatitis rarely occur in rela-
tion to flucloxacillin intake, with the risk factors being the
patient’s age, preexisting hepatic impairment, and long-term
use (14 days [3]). In a population-based case-control study,
de Abajo et al. (16) identified a dose dependency for these
adverse effects. It remains to be determined whether high peak
concentrations, total exposure, or trough concentrations con-
tribute to the frequency of adverse events for flucloxacillin.
However, prolonged and continuous infusions allow a signifi-
cant dose reduction and avoid high peak concentrations, while
they achieve the same PTAs as short-term infusion.
Whether prolonged or continuous infusion would be used
depends on the clinical situation of the patient. The continuous
infusion of flucloxacillin may be used for the home treatment
of MSSA infections that require high-dose intravenous treat-
ment over prolonged time periods. This procedure has been
shown to be safe, convenient, and effective for the follow-up
treatment of serious staphylococcal infections (e.g., sepsis, en-
docarditis, and osteomyelitis) and cellulitis (22, 23), and flu-
cloxacillin solutions have also been reported to have sufficient
stability at room temperature (26). However, in the hospital
setting and with patients receiving multiple intravenous drugs,
one of the major drawbacks of continuous infusion is the need
for an additional infusion line to prevent incompatibilities with
other drugs and the resulting increase of the risk for line
infections (25).
In conclusion, we found that the PK of flucloxacillin is linear
for the doses of 500 mg and 1,000 mg administered as 5-min
intravenous infusions. For near maximal killing (target, an
fTMIC of 50%) flucloxacillin showed a robust (90%) PTA
up to MICs of 0.75 to 1 mg/liter (PTA of 86% at 1 mg/liter) for
prolonged infusions or a continuous infusion of 6 g/day. Short-
term infusions of 6 g/day given q6h had a lower breakpoint of
0.25 to 0.375 mg/liter (PTA of 79% at 0.375 mg/liter). For an
MIC90 of 0.5 mg/liter, which is typically found for flucloxacillin
against MSSA, prolonged and continuous infusion at a daily
dose of 4 g had an expectation value for the population PTA of
at least 90%. To achieve the same expectation value, a daily
dose of 12 g given as short-term infusions given q6h would be
required. This dose reduction from 12 g/day for short-term
infusion to 4 g/day for prolonged infusion and continuous
infusion might be a considerable advantage in terms of the risk
for adverse events and drug acquisition costs. Future compar-
ative clinical trials are warranted to show whether prolonged
and continuous infusions of flucloxacillin at lower dose levels
FIG. 4. Unbound concentrations and median and prediction interval (5th to 95th percentile) of the fTMIC at steady state in healthy volunteers
after a 30-min infusion of 1.5 g q6h (continuous line, marker F), after a 4-h infusion of 2 g q8h (dashed line, marker f), and after continuous
infusion of 6 g per day (dashed line, marker ) (bottom left panel) and after a 30-min infusion of 2 g q4h (continuous line, marker f) (bottom
right panel). We assumed a fixed protein binding of 96% for the simulations. The curve for the 4-h infusion was shifted to the right by 6% in the
MIC for easier identification of the corresponding prediction intervals (5th to 95th percentile). The 5th and 95th percentiles for the continuous
infusion were omitted for clarity. After continuous infusion, more than 99% of the subjects had an fTMIC of 100% at an MIC of 0.75 mg/liter.
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achieve similar or better clinical success rates than short-term
infusion.
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